Thiotepa

Generic Name: Thiotepa

Brand Names: Tepadina, Thiotepa Riemser

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₃PS

CAS Number: 52-24-4

Unique Ingredient Identifier: 905Z5W3GKH

Background: N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...

Indication: ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions: Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion

Associated Therapies: -

Clinical Trials

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

First Posted Date: 2019-02-21

Last Posted Date: 2024-08-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 140

Registration Number: NCT03849651

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 2

Active, not recruiting

Conditions: Ganglioneuroblastoma
High Risk Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Dexrazoxane
Biological: Dinutuximab
Drug: Doxorubicin
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Drug: Isotretinoin
Drug: Melphalan
Biological: Sargramostim
Drug: Thiotepa
Drug: Topotecan
Drug: Vincristine

First Posted Date: 2018-12-26

Last Posted Date: 2024-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT03786783

Locations: 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿
Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺
The Children's Hospital at Westmead, Westmead, New South Wales, Australia

and more 7 locations

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

First Posted Date: 2018-12-19

Last Posted Date: 2024-11-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 68

Registration Number: NCT03779854

Locations: 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 7 locations

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Phase 1

Recruiting

Conditions: Diamond-blackfan Anemia
Sickle Cell Anemia
Beta-thalassemia Major

Interventions: Biological: CD3/CD19 depleted leukocytes
Biological: CD45RA depleted leukocytes
Drug: Hydroxyurea
Drug: Rituximab
Drug: Alemtuzumab
Drug: Fludarabine
Drug: Thiotepa

First Posted Date: 2018-08-31

Last Posted Date: 2024-08-09

Lead Sponsor: Paul Szabolcs

Target Recruit Count: 5

Registration Number: NCT03653338

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Phase 2

Recruiting

Conditions: Diffuse Sclerosis Systemic
Interstitial Lung Disease
Pulmonary Hypertension
Systemic Sclerosis

Interventions: Drug: Cyclophosphamide
Drug: Mesna
Drug: Rituximab
Drug: Alemtuzumab
Drug: Thiotepa
Drug: GM-CSF
Drug: Intravenous immunoglobulin
Radiation: Total Body Irradiation
Drug: Anti Thymocyte Globulin

First Posted Date: 2018-08-14

Last Posted Date: 2024-08-09

Lead Sponsor: Paul Szabolcs

Target Recruit Count: 8

Registration Number: NCT03630211

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Phase 2

Terminated

Conditions: Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoid Leukemia (ALL)
Chronic Myeloid Leukemia (CML)
Hodgkin Lymphoma
Acute Myeloid Leukemia (AML)

Interventions: Radiation: Hyperfractionated total body irradiation
Drug: Busulfan
Drug: Thiotepa
Drug: Fludarabine
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Clofarabine
Procedure: HPC(A) stem cell allograft
Drug: Rituximab
Device: Rabbit antithymocyte globulin

First Posted Date: 2018-08-03

Last Posted Date: 2024-03-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT03615105

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Phase 2

Terminated

Conditions: Non-Malignant Hematologic Disorders

Interventions: Drug: Melphalan
Drug: Thiotepa
Drug: Clofarabine
Drug: Fludarabine
Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
Procedure: CliniMACS reagents

First Posted Date: 2018-08-03

Last Posted Date: 2021-03-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT03615144

Locations: 🇺🇸
Memorial SloanKettering Cancer Center, New York, New York, United States

Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Completed

Conditions: Immune Deficiency
Thalassemia
Hemoglobinopathies
Fanconi Anemia
Sickle Cell Disease
Nonmalignant Diseases
Hematologic Malignancies
Genetic Inborn Errors of Metabolism

Interventions: Drug: Thiotepa

First Posted Date: 2018-08-01

Last Posted Date: 2023-09-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 25

Registration Number: NCT03609840

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Phase 1

Active, not recruiting

Conditions: Severe Combined Immunodeficiency

Interventions: Drug: Anti-thymocyte globulin (rabbit)
Drug: Busulfan
Other: Donor Lymphocyte Infusion
Drug: Fludarabine
Drug: Thiotepa
Device: CliniMACS

First Posted Date: 2018-07-24

Last Posted Date: 2024-06-12

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT03597594

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Phase 1

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis
Emphysema or COPD

Interventions: Biological: CD3/CD19 negative hematopoietic stem cells
Drug: Rituximab
Drug: Alemtuzumab
Drug: Fludarabine
Drug: Thiotepa
Drug: G-CSF
Drug: Hydroxyurea

First Posted Date: 2018-04-18

Last Posted Date: 2024-01-05

Lead Sponsor: Paul Szabolcs

Target Recruit Count: 8

Registration Number: NCT03500731

Locations: 🇺🇸
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy